Skip to content

Scott Breitinger

Mayo Clinic Department of Psychiatry and Psychology, USA.

2 papers in the library · 2 citations · publishing 2024-2025

Papers

Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse

The Journal of Clinical Psychiatry August 25, 2024 Mark A. Frye, Balwinder Singh, Scott Breitinger et al. 2 citations

A man with alcohol use disorder (AUD) maintained sobriety while taking an SSRI and naltrexone, but stopped the SSRI to take part in a psilocybin ceremony, after which he relapsed to alcohol use. The case examines factors that likely contributed to the relapse, including the discontinuation of the SSRI, the context of the psilocybin experience, and the absence of structured follow-up care.

Innovation and inequity in psychedelic research at the Mayo Clinic.

History of psychiatry April 28, 2025 Casimir Klim, Bryan VanDreese, Terence Meyerhoefer et al.

In the 1950s and 1960s, researchers at the Mayo Clinic conducted studies with psychedelic drugs, including LSD and psilocybin. Their work sometimes prioritized scientific advancement over the rights and safety of participants, raising ethical concerns about informed consent and equitable treatment. These historical problems continue to challenge contemporary psychedelic research.